Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586117 | 0.90 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL31603834 | 0.89 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL2182381 | 0.88 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL851166 | 0.87 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL302663 | 0.86 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL302512 | 0.86 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL20211763 | 0.86 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL2184223 | 0.86 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL8551794 | 0.85 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA | |
| SCHEMBL8204708 | 0.85 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119971404-A | Fire extinguishing agent and preparation method thereof | 宋炜 | 2025-05-13 | — | — | CN | claimed |
| CN-118546293-A | Modified polyacrylamide containing degradable hydrophobic monomer and preparation method thereof | 西南石油大学 | 2024-08-27 | — | — | CN | claimed |
| CN-117747739-A | Preparation method of ionic compound and supermolecular skeleton assembly, artificial solid electrolyte interface phase and zinc metal anode | 吉林大学 | 2024-03-22 | — | — | CN | claimed |
| CN-117343319-A | Cationic polyamide-amine flocculant containing degradable imine bond and preparation method and application thereof | 西南石油大学 | 2024-01-05 | — | — | CN | claimed |
| CN-116023298-A | PH responsive surfactant with dynamic imine bond, and preparation and application thereof | 中国石油化工股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-115232319-A | Supermolecule polyaldehyde compound based on poly-beta-cyclodextrin and ferrocene host-guest action and preparation method thereof | 四川大学 | 2022-10-25 | — | — | CN | claimed |
| CN-115160454-A | Supermolecule polyaldehyde compound based on poly-beta-cyclodextrin and adamantane host-guest action and preparation method thereof | 四川大学 | 2022-10-11 | — | — | CN | claimed |
| CN-111514107-B | Active oxygen response type vesicle and preparation method thereof | 江南大学 | 2021-12-21 | — | — | CN | claimed |
| CN-111514107-A | Active oxygen response type vesicle and preparation method thereof | 江南大学 | 2020-08-11 | — | — | CN | claimed |
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2007-06-21 | — | — | US | claimed |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | US | claimed |
| US-7192970-B2 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-03-20 | — | — | US | claimed |
| US-20040138211-A1 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2004-07-15 | — | — | US | claimed |
| WO-2004048338-A1 | NONCYCLIC 1,3-DICARBONYL COMPOUNDS AS DUAL PPAR AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (US) | 2004-06-10 | — | — | WO | claimed |
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2026-04-16 | — | — | US | disclosed |
| CN-121226640-A | Polymer gel profile control system and preparation method thereof | 西南石油大学 | 2025-12-30 | — | — | CN | disclosed |
| EP-4637734-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARy AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2025-10-29 | — | — | EP | disclosed |
| US-4983633-A | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0306827-A1 | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-03-15 | — | — | EP | disclosed |
| US-4465684-A | ANTIDIABETIC, ANTILIPEMIC AGENT | BAYER AKTIENGESELLSCHAFT (DE) | 1984-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | ALDH1A1 3570/4885SMN1; SMN2 4879/4885MAPT 4832/4885 |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, NSUN3, POLR2H | ALDH1A1 3520/4885SMN1; SMN2 1141/4885MAPT 4865/4885 |
| US-20040138211-A1 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | PPARG, GPR119, PPARA | ALDH1A1 3236/4885SMN1; SMN2 4870/4885MAPT 4836/4885 |
| US-20260102390-A1 | 4-(2-(4-((2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL)PHENOXY) DERIVATIVES AS PPARgamma AGONISTS AND AUTOTAXIN INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | PPARG, FABP1, PPARA | ALDH1A1 1965/4885SMN1; SMN2 221/4885MAPT 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.